The Lynx Group

Emerging Therapies

Atlanta, GA—Mogamulizumab, a monoclonal antibody targeting CC chemokine receptor type 4 (CCR4), significantly reduced the risk for disease progression or death in patients with untreated cutaneous T-cell lymphoma (CTCL) compared with vorinostat (Zolinza), reported Youn H. Kim, MD, Director, Multidisciplinary Cutaneous Lymphoma Program, Stanford Medicine, California, at ASH 2017.
Read Article

Chicago, IL—A new high-intensity genomic sequencing strategy (developed by Grail Inc) detects circulating tumor DNA (ctDNA) at a high rate. The new approach is a major improvement on previous tests using ctDNA, which focus on a limited number of driver mutations to inform treatment strategies for metastatic disease or to monitor disease burden. The new test offers ultra-deep sequencing with a broad genomic coverage, but it is not ready for prime time to detect occult cancer. At present, the test is a research platform and is not commercially available.
Read Article

Chicago, IL—Oral cediranib, an investigational vascular endothelial growth factor (VEGF) inhibitor, in combination with a poly ADP-ribose polymerase (PARP) inhibitor or with chemotherapy, shows survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to data from 2 studies presented at the 2017 ASCO annual meeting.
Read Article

Chicago, IL—The investigational, second-generation EGFR inhibitor dacomitinib reduced the risk for disease progression compared with gefitinib as first-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) and EGFR mutation. Results from the phase 3 ARCHER 1050 clinical trial demonstrated a >40% reduction in the risk for disease progression and an average 6.5-month improvement in the duration of response with dacomitinib versus gefitinib.
Read Article

Chicago, IL—Larotrectinib (LOXO-101), an investigational agent that targets tropomyosin receptor kinase (TRK) fusions, has demonstrated excellent, consistent, and durable antitumor activity in a range of tumor types in adults and children, reported lead investigator David M. Hyman, MD, Chief, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2017 ASCO annual meeting. Larotrectinib was called “the first oral tumor-agnostic therapy,” because of its unprecedented high response rates in 17 tumor types that express TRK.
Read Article

Orlando, FL—Prophylaxis with letermovir beginning after hematopoietic-­cell transplantation (HCT) and lasting through 100 days reduced the risk for clinically significant cytomegalovirus (CMV) infection. Furthermore, letermovir was associated with lower all-cause mortality compared with placebo, reported Francisco M. Marty, MD, Associate Professor of Medicine, Harvard Medical School, Boston, at the 2017 BMT Tandem Meetings.
Read Article

Hollywood, FL—A basket study of the oncolytic immunotherapy PV-10 (10% Rose Bengal disodium for injection), which included patients with tumors originating in various locations, showed that data for gastrointestinal lesions were especially encouraging, reported Paul M. Goldfarb, MD, FACS, a surgeon at Oncology Associates of San Diego, CA, at the 2017 Clinical Interventional Oncology annual symposium.
Read Article

San Diego, CA—Anti-CD19 chimeric antigen receptor (CAR) T-cell administration after autologous stem-cell transplant (ASCT) showed clinical activity in patients with advanced multiple myeloma, according to results of a pilot study presented at the 2016 American Society of Hematology meeting. Substantially longer progression-free survival (PFS) was seen in 2 of 10 patients who received ASCT plus CTL019 than in patients who received first-line ASCT, said Alfred L. Garfall, MD, MS, Assistant Professor of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia.
Read Article

San Diego, CA—Ropeginterferon alfa-2b, an investigational, long-acting, mono-pegylated interferon was noninferior to hydroxyurea in achieving complete hematologic response and with superior tolerability to hydroxyurea in the treatment of patients with polycythemia vera, according to the final results of the phase 3 PROUD-PV clinical trial presented by Heinz Gisslinger, MD, Medical University of Vienna, Austria, at the 2016 American Society of Hematology meeting.
Read Article

San Diego, CA—Chimeric antigen receptor (CAR)-targeting CD22 therapy induced clinical responses and a high rate of complete remission in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL), including patients who had received anti-CD19 CAR T-cell therapy, said Terry J. Fry, MD, Hematologic Malignancies Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), at the 2016 American Society of Hematology meeting. These findings create the opportunity for bispecific or multispecific CAR T-cell targeting.
Read Article

Page 3 of 6

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: